CJC-1295 (with DAC)
CJC-1295 DAC / Drug Affinity Complex CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to serum albumin, extending its half-life to 6-8 days. Developed by ConjuChem Biotechnologies, it produces sustained elevation of growth hormone and IGF-1 levels from a single weekly injection. It is primarily researched for growth hormone deficiency, muscle wasting, and age-related GH decline.
作用機序
Modified GHRH analog conjugated to a Drug Affinity Complex (DAC) that binds serum albumin, dramatically extending half-life. Produces sustained elevation of GH and IGF-1 levels rather than pulsatile release. Continuously stimulates GHRH receptors.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols use 1-2mg once or twice weekly via subcutaneous injection. The long half-life means GH elevation is sustained, not pulsatile. Less frequent dosing but different pharmacodynamic profile than no-DAC version.
研究ノート
Clinical Research Status
CJC-1295 with DAC reached Phase 2 clinical trials before development was discontinued following a participant death attributed to a myocardial infarction (causality was debated). Published trials demonstrated significant and sustained increases in GH and IGF-1 with weekly or biweekly dosing. The compound remains available through research suppliers despite the halted clinical program.
Key Published Findings
A single 30-60mcg/kg injection produced sustained GH elevation for 6+ days and IGF-1 increases of 1.5-3x baseline lasting up to 2 weeks. The GHRH analog demonstrated dose-proportional pharmacokinetics with predictable IGF-1 responses. Studies showed increases in lean body mass and reductions in visceral fat with repeated administration.
Safety Profile
The sustained GH elevation raises theoretical concerns about prolonged IGF-1 exposure compared to pulsatile protocols. Common side effects include injection site reactions, water retention, paresthesias, and headache. The extended half-life means side effects may persist for days rather than hours, making dose titration more challenging.
Drug Interactions & Contraindications
Same contraindications as the no-DAC variant apply, with additional concern regarding the inability to quickly discontinue effects due to the long half-life. Not recommended in combination with exogenous GH as this may cause excessive IGF-1 elevation. Contraindicated in diabetic patients due to GH's insulin-antagonistic effects at sustained high levels.
Comparison to Related Compounds
The DAC variant provides convenience of weekly dosing but sacrifices the physiological pulsatile GH pattern that the no-DAC version produces. Most researchers now prefer the no-DAC version combined with a GHRP for a more natural GH profile with better safety margins. The sustained elevation from DAC may increase risk of side effects associated with chronic GH excess (joint pain, insulin resistance, fluid retention).
Community Observations
Typically dosed at 1-2mg once or twice weekly via subcutaneous injection. Less popular than the no-DAC variant among experienced users due to concerns about blunted GH pulsatility and potential for desensitization. Some users combine it with GHRPs on non-injection days to maintain pulsatile stimulation alongside the baseline elevation.
半減期
~6-8 days
再構成
Bacteriostatic water (BAC)
保存
乾燥粉末
Refrigerate 2-8C up to 24 months.
再溶解
Refrigerate 2-8C. Use within 30 days.
米国法的状況
また知られる名前
よくある質問
CJC-1295 (with DAC)とは何ですか?
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to serum albumin, extending its half-life to 6-8 days. Developed by ConjuChem Biotechnologies, it produces sustained elevation of growth hormone and IGF-1 levels from a single weekly injection. It is primarily researched for growth hormone deficiency, muscle wasting, and age-related GH decline.
CJC-1295 (with DAC)はどのように作用しますか?
Modified GHRH analog conjugated to a Drug Affinity Complex (DAC) that binds serum albumin, dramatically extending half-life. Produces sustained elevation of GH and IGF-1 levels rather than pulsatile release. Continuously stimulates GHRH receptors.
CJC-1295 (with DAC)の米国での規制状況は?
Research chemical (not FDA-approved)
CJC-1295 (with DAC)の半減期は?
~6-8 days
CJC-1295 (with DAC)の別名は?
CJC-1295 DAC, Drug Affinity Complex CJC-1295
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む